Streetbeat News

DOCS

Doximity, Inc.

https://www.doximity.com

Industry

Medical - Healthcare Information Services

Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.

Open

42.41

Mkt cap

8.1B

Volume

2.7M

High

43.74

P/E Ratio

54.28

52-wk high

44.88

Low

42.36

Div yield

N/A

52-wk low

20.28

Doximity (NYSE:DOCS) reported Q2 earnings of $0.22 per share, beating the analyst consensus estimate of $0.18 by 22.22%. This is a 29.41% increase from the same period last year. The company also reported quarterly sales of $113.61 million, beating the analyst consensus estimate of $109.06 million by 4.17%. This is an 11.18% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 9:54 pm

Doximity Inc's Q2 results exceeded expectations with revenue of $113.6 million, up 11% YoY, and adjusted earnings of 22 cents per share. The company's board authorized a buyback of up to $70 million over the next 12 months. Doximity expects Q3 revenue to be between $127 million and $128 million, and full-year revenue of $460 million to $472 million.

Portfolio Pulse from Adam Eckert

November 09, 2023 | 9:51 pm

Several healthcare stocks experienced significant movement in Thursday's after-market session. TRACON Pharma, Doximity, AVITA Medical, Cano Health, DarioHealth, and Evaxion Biotech saw increases, with TRACON Pharma leading with a 71.3% increase. On the other hand, Treace Medical Concepts, Sensus Healthcare, Biolase, TELA Bio, Syndax Pharmaceuticals, and Quantum-Si experienced decreases, with Treace Medical Concepts leading the decline with a 24.1% decrease. Most of these movements were associated with the release of Q3 earnings reports.

Portfolio Pulse from Benzinga Insights

November 09, 2023 | 9:31 pm

Doximity (NYSE:DOCS) reported its Q2 earnings, beating estimated earnings by 22.22% with an EPS of $0.22 versus an estimate of $0.18. Revenue was up $11.43 million from the same period last year. Last quarter, the company beat on EPS by $0.04, which was followed by a 22.84% drop in the share price the next day.

Portfolio Pulse from Benzinga Insights

November 09, 2023 | 9:05 pm

Benzinga's options activity scanner has identified unusual options activity in the Health Care sector. The stocks involved are AstraZeneca (AZN), Elanco Animal Health (ELAN), Abbott Laboratories (ABT), DexCom (DXCM), Doximity (DOCS), Johnson & Johnson (JNJ), GE Healthcare (GEHC), Agilent Technologies (A), Inspire Medical Systems (INSP), and Biogen (BIIB). The options activity ranges from bullish to bearish and neutral sentiments.

Portfolio Pulse from Benzinga Insights

October 23, 2023 | 5:35 pm

Doximity (NYSE:DOCS) has received mixed analyst ratings in the last quarter, with 1 bullish, 1 somewhat bullish, 3 indifferent, and 1 somewhat bearish. The average 12-month price target for Doximity is $28.83, representing a 19.92% decrease from the previous average price target of $36.00.

Portfolio Pulse from Benzinga Insights

September 05, 2023 | 7:00 pm

Canaccord Genuity analyst Richard Close has maintained a 'Buy' rating on Doximity (NYSE:DOCS) but lowered the price target from $40 to $33.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 4:29 pm

Benzinga's options activity scanner has identified unusual trading activity in 10 health care stocks. The stocks include Johnson & Johnson (JNJ), Moderna (MRNA), Apellis Pharmaceuticals (APLS), Pfizer (PFE), Boston Scientific (BSX), CVS Health (CVS), Zimmer Biomet Holdings (ZBH), Cassava Sciences (SAVA), Reata Pharmaceuticals (RETA), and Doximity (DOCS). The scanner tracks large transactions, known as 'whale alerts', which can indicate the sentiment of large investors and potentially predict market movements.

Portfolio Pulse from Benzinga Insights

August 14, 2023 | 5:35 pm

Wells Fargo analyst Stan Berenshteyn maintains an Equal-Weight rating on Doximity (NYSE:DOCS) and lowers the price target from $37 to $25.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:05 am

The article lists the stocks that gained and lost the most in Wednesday's trading session. Among the gainers, Tango Therapeutics, Decibel Therapeutics, and Benitec Biopharma saw significant increases due to recent positive financial results and acquisition news. Among the losers, Palisade Bio, Tigo Energy, and Nxu saw significant decreases due to disappointing financial results and negative news.

Portfolio Pulse from Lisa Levin

August 09, 2023 | 7:17 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.